| Characteristic | Exposure to treatment | Duration of treatment | ||
|---|---|---|---|---|
| Antihypertensive agents Adjusted OR (95% CI) | Cholesterol treatments Adjusted OR (95% CI) | Antihypertensive agents β (95% CI) | Cholesterol treatments β (95% CI) | |
| Age (69 = reference), yr | ||||
| 70 | 1.01 (0.94 to 1.08) | 1.10 (1.03 to 1.17) | 2.1 (-9.1 to 13.3) | -0.7 (-7.7 to 6.2) |
| 71 | 1.15 (1.07 to 1.24) | 1.10 (1.03 to 1.18) | 9.1 (-2.2 to 20.5) | -3.5 (-10.5 to 3.6) |
| 72 | 1.14 (1.06 to 1.24) | 1.14 (1.06 to 1.22) | 17.6 (5.9 to 29.4) | -2.1 (-9.4 to 5.2) |
| 73 | 1.19 (1.10 to 1.29) | 1.19 (1.11 to 1.28) | 14.5 (2.5 to 26.5) | -2.1 (-9.5 to 5.3) |
| Health: no. of major ADGs (0 = reference) | ||||
| 1 to 2 | 1.30 (1.23 to 1.37) | 1.26 (1.20 to 1.32) | 14.7 (6.5 to 22.8) | 4.7 (-0.5 to 9.8) |
| ≥ 3 | 1.34 (1.21 to 1.49) | 1.39 (1.28 to 1.52) | -1.4 (-15.2 to 12.5) | -5.6 (-14 to 2.7) |
| Diagnoses of specific indications, EDC codes | ||||
| CAR14 or CAR15: Hypertension | 27.25 (25.86 to 28.72) | 90.3 (81.2 to 99.3) | ||
| CAR01: cardiovascular signs and symptoms | 1.36 (1.28 to 1.46) | 6.7 (-2.3 to 15.6) | ||
| CAR05: Congestive heart failure | 5.25 (4.35 to 6.35) | 66.5 (48.9 to 84.2) | ||
| CAR07: Cardiomyopathy | 11.62 (5.73 to 23.56) | 48.5 (5.8 to 91.2) | ||
| END06 or END07: type 1 diabetes | 13.24 (5.42 to 32.3) | 210.5 (111 to 309.9) | ||
| END08 or END09: type 2 diabetes | 6.9 (6.46 to 7.38) | 117.9 (109.4 to 126.4) | ||
| CAR03: Ischemic heart disease | 2.59 (2.34 to 2.87) | 2.68 (2.49 to 2.87) | 60.9 (49.4 to 72.4) | 10.6 (4.2 to 17.1) |
| CAR10: Generalized atherosclerosis | 2.06 (1.54 to 2.76) | 2.08 (1.7 to 2.54) | 61.1 (29.5 to 92.7) | 15.6 (-0.8 to 31.9) |
| CAR12: Acute myocardial infarction | 3.39 (2.01 to 5.7) | 2.62 (2.03 to 3.38) | -21 (-56.4 to 14.4) | -54.6 (-72.4 to -36.9) |
| CAR11: Disorders of lipoid metabolism | 3.21 (3.02 to 3.4) | -20.6 (-26.1 to -15.2) | ||
| NUR05: Cerebrovascular disease | 2.3 (2.07 to 2.55) | -3.1 (-12.2 to 6.01) | ||
| Ethnicity (white/other = reference) | ||||
| Chinese | 0.63 (0.57 to 0.69) | 1.24 (1.14 to 1.34) | -49.5 (-64 to -35) | -3.2 (-11.4 to 5) |
| South Asian | 0.83 (0.73 to 0.94) | 1.44 (1.30 to 1.60) | -10.9 (-28.6 to 6.8) | -17.4 (-27.4 to -7.3) |
| Setting (urban/suburban = reference) | ||||
| Rural setting | 1.10 (1.01 to 1.21) | 0.94 (0.86 to 1.02) | 6.6 (-6.6 to 19.7) | -0.4 (-8.9 to 8.2) |
| Income (< 15 000 = reference), $ | ||||
| 15 000-29 999 | 1.01 (0.86 to 1.20) | 1.19 (1.03 to 1.37) | 34.4 (10.6 to 58.2) | 5.6 (-8.7 to 19.9) |
| 30 000-32 999 | 0.89 (0.73 to 1.09) | 1.15 (0.97 to 1.37) | 47.5 (18.5 to 76.4) | -0.4 (-17.8 to 17) |
| 33 000-42 999 | 0.99 (0.83 to 1.17) | 1.12 (0.97 to 1.30) | 52.6 (28.0 to 77.1) | 11.7 (-3.0 to 26.5) |
| 43 000-49 999 | 0.96 (0.81 to 1.15) | 1.05 (0.90 to 1.23) | 46.6 (21.2 to 72.0) | 12.5 (-2.8 to 27.8) |
| 50 000-56 999 | 1.00 (0.83 to 1.19) | 1.11 (0.95 to 1.30) | 44.8 (18.8 to 70.8) | 17.6 (2.0 to 33.3) |
| 57 000-69 999 | 1.02 (0.86 to 1.22) | 0.96 (0.82 to 1.13) | 40.6 (14.8 to 66.4) | 19.3 (3.7 to 34.9) |
| ≥ 70 000 | 0.93 (0.78 to 1.10) | 0.89 (0.77 to 1.03) | 35.5 (10.9 to 60.1) | 23.6 (8.8 to 38.4) |
| PharmaCare assistance (standard = reference), $ | ||||
| Enhanced, < 50 000 | 1.15 (1.06 to 1.24) | 1.13 (1.06 to 1.21) | 7.5 (-3.6 to 18.7) | 6.1 (-0.7 to 12.8) |
| Enhanced, > 50 000 | 0.98 (0.91 to 1.04) | 1.08 (1.01 to 1.15) | 4.1 (-6.2 to 14.5) | -0.3 (-6.7 to 6.2) |
Note: Bolded estimates are statistically significant (p < 0.05). ADG = aggregated diagnostic group, CI = confidence interval, ECD = episode-specific disease category, OR = odds ratio.